

DEC 12 2002

510(k) Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, Address, and Contact

Lin-Zhi International, Inc.
2391 Zanker Road, Suite 340
San Jose, CA 95131-1124
Phone: (408) 944-0360
Fax: (408) 944-0359

Contact: Chiu Chin Chang, Ph.D.
VP, R&D

Device Name and Classification

Classification Name: Methadone test system, Class II, DJR (91 Toxicology),
21CFR 862.3620
Common Name: Homogeneous enzyme immunoassay for the determination of
methadone levels in urine.
Proprietary Name: None

Legally Marketed Predicate Device(s)

Lin-Zhi International, Inc.'s Methadone Enzyme Immunoassay is substantially equivalent to the Methadone Enzyme Immunoassay (By DRI/Microgenics Corp.), cleared under premarket notification K972526.

LZI's Methadone Enzyme Immunoassay is identical or similar to its predicate in terms of intended use, method principle, device components, and clinical performance.

Device Description

LZI's Methadone Enzyme Immunoassay is a ready-to-use, liquid reagent, homogeneous enzyme immunoassay. The assay uses specific antibody that can detect methadone in human urine with minimal cross-reactivity to various, common prescription drugs and abused drugs.

The assay is based on competition between methadone labeled with glucose-6-phosphate dehydrogenase (G6PDH) enzyme and free drug from the urine sample for a fixed amount of specific antibody. In the absence of free drug from the urine sample the specific antibody binds to the drug labeled with G6PDH enzyme causing a decrease in enzyme activity. The G6PDH enzyme activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.

Intended Use

The Methadone Enzyme Immunoassay is a homogeneous enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semi-quantitative analyses of methadone in human urine.

Comparison to Predicate Device

LZI's Methadone Enzyme Immunoassay is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to the currently, commercially marketed Methadone Enzyme Immunoassay (K972526) by DRI/Microgenics Corporation.

The following table compares LZI's Methadone Enzyme Immunoassay with the predicate device, Methadone Enzyme Immunoassay by DRI/Microgenics Corp.

Similarities:

- Both assays are for qualitative and semi-quantitative determination of methadone in human urine.
- Both assays use the same method principle, and device components.
- Both assays use 300 ng/mL as cutoff level.

(Comparison to Predicate Device, continued)

Performance Characteristics

Feature	DRI's Methadone EIA				LZI's Methadone EIA			
Within Run Precision:								
Qualitative:	<u>Mean Rate</u>	<u>SD</u>	<u>% CV</u>		<u>Mean Rate</u>	<u>SD</u>	<u>% CV</u>	
Negative	127	1.0	0.8		Negative	209.4	1.0	0.49
300 ng/mL	217	1.6	0.7		225 ng/mL	272.8	1.1	0.39
1000 ng/mL	289	1.5	0.5		300 ng/mL	293.4	0.7	0.25
					375 ng/mL	308.2	0.9	0.29
					1000 ng/mL	344.9	1.1	0.33
Semi-quantitative:	No data available				<u>Mean Conc.</u>	<u>SD</u>	<u>% CV</u>	
					225 ng/mL	229.2	2.5	1.09
					300 ng/mL	308.5	3.5	1.13
					375 ng/mL	391.4	5.4	1.37
Run-To-Run Precision:								
Qualitative:	No data available				<u>Mean Rate</u>	<u>SD</u>	<u>% CV</u>	
					Negative	209.5	1.1	0.51
					225 ng/mL	271.4	2.0	0.74
					300 ng/mL	292.3	1.9	0.66
					375 ng/mL	307.2	2.6	0.84
					1000 ng/mL	344.1	2.0	0.58
Semi-quantitative:	No data available				<u>Mean Conc.</u>	<u>SD</u>	<u>% CV</u>	
					225 ng/mL	228.0	7.8	3.42
					300 ng/mL	305.1	10.2	3.36
					375 ng/mL	379.6	13.2	3.47
Sensitivity:	10 ng/mL				15 ng/mL			
Accuracy:	Vs. a commercial EIA				Vs. GC/MS			
Positive Samples:	100 % agreement (GC/MS confirmed)				100 % agreement			
Negative Samples:	100 % agreement				100 % agreement			
Analytical Recovery:								
Qualitative:	No data available				100 % accuracy on positive vs. negative tests			
Semi-quantitative:	No data available				Quantitates within $\pm 15\%$ of the nominal concentration between 30 ng/mL and 750 ng/mL. Average 96.6 % recovery at 225 ng/mL level (Cutoff -25%) Average 93.7 % recovery at 375 ng/mL level (Cutoff + 25%)			
Specificity:	See attached DRI's Methadone EIA package insert				Comparable to the predicate device.			

Conclusion

LZI's Methadone Enzyme Immunoassay was evaluated for several performance characteristics including precision, sensitivity, accuracy, analytical recovery, and specificity. All the studies showed acceptable results when compared to the predicate device.

We trust the information provided in this Premarket Notification [510(k)] submission will support a determination of substantial equivalence of the LZI's Methadone Enzyme Immunoassay to other methadone test systems currently marketed in the United States.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Chiu Chin Chang, Ph.D.
VP, R & D
Lin-Zhi International, Inc.
687 North Pastoria Avenue
Sunnyvale, CA 94085-2917

DEC 12 2002

Re: k023317
Trade/Device Name: Methadone Enzyme Immunoassay
Regulation Number: 21 CFR 862.3620
Regulation Name: Methadone test system
Regulatory Class: Class II
Product Code: DJR
Dated: September 30, 2002
Received: October 3, 2002

Dear Dr. Chang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

Premarket Notification

Indications for Use Statement


510(k) Number (if known): K023317

Device Name: **Methadone Enzyme Immunoassay**

Indications for Use:

The Methadone Enzyme Immunoassay is a homogeneous enzyme immunoassay with a 300 ng/mL cutoff. The assay is intended for use in the qualitative and semi-quantitative analyses of methadone in human urine. The assay is designed for professional use with a number of automated clinical chemistry analyzers.

The Methadone Enzyme Immunoassay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgement should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.


(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K023317

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)